With quarterly earnings underway, BioPharma Dive is providing a snapshot of some companies’ results and how they’re being received by investors. A third closely watched by investors, Yeztugo, hit $232 million, in-line with expectations and putting the drug on track to hit Gilead’s $1 billion projection this year. But Gilead’s “strong operational performance” gives it a “higher base” with which to weather any coming erosion, wrote RBC Capital Markets’ Brian Abrahams. To Leerink Partners analyst Daina Graybosch, there were “several uncertain Yeztugo signals” in Gilead’s presentation. A $43 billion buyout of Seagen was designed to solidify Pfizer’s oncology prospects, while a $10 billion purchase of Metsera gave the company a crack at the lucrative obesity drug market.